The Use of Silymarin in the Treatment of Liver Diseases
Top Cited Papers
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 61 (14) , 2035-2063
- https://doi.org/10.2165/00003495-200161140-00003
Abstract
The high prevalence of liver diseases such as chronic hepatitis and cirrhosis underscores the need for efficient and cost-effective treatments. The potential benefit of silymarin (extracted from the...Keywords
This publication has 100 references indexed in Scilit:
- Selective inhibition of NF‐κB activation by the flavonoid hepatoprotector silymarin in HepG2FEBS Letters, 1998
- Long-term (23 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patientsJournal of Hepatology, 1997
- Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibininHepatology, 1996
- Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cellsLife Sciences, 1996
- Hepatoprotective mechanism of silymarin: No evidence for involvement of cytochrome P450 2E1Chemico-Biological Interactions, 1994
- Comparative bioavailability of Silipide, a new flavanolignan complex, in ratsEuropean Journal of Drug Metabolism and Pharmacokinetics, 1992
- Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjectsEuropean Journal of Drug Metabolism and Pharmacokinetics, 1990
- Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liverJournal of Hepatology, 1989
- Untersuchungen zur Elimination von Silymarin bei cholezystektomierten PatientenPlanta Medica, 1982
- Prevention by silybin of phalloidin-induced acute hepatoxicityToxicology and Applied Pharmacology, 1979